SpyGlass Pharma SGP
NASDAQ SGP
$28.48 +0.26 (+0.92%)
At close: Oct 23, 2026 · 4:00 PM EDT

SpyGlass Pharma (SGP) Cash & Equivalents (2024 - 2026)

Updated

SpyGlass Pharma's Cash & Equivalents came in at $223.14 million for Q2 2026.

Analysis

SpyGlass Pharma (SGP) Cash & Equivalents (2024 - 2026) Analysis & Trends

At the end of FY2025, SpyGlass Pharma's Cash & Equivalents was $96.36 million, up 492.3% from FY2024.

  • Going back by year, Cash & Equivalents was $16.27 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 16.91 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 6.57 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 4.90 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 3.18 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 976.00 Mn
10 SpyGlass Pharma 952.55 Mn 718.37 Mn - 223.14 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 223.14 Mn
Dec 31, 2025 96.36 Mn
Dec 31, 2024 16.27 Mn
API Access

SpyGlass Pharma Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=SGP&period=max&api_key=YOUR_API_KEY